




Name	Maximilian Stahl	
Current Position	Instructor of Medicine Harvard Medical School	
Country	USA	
Major Field	Medical Oncology (Leukemia)	

Educational Background

2013: Graduation from Hannover Medical School, Hannover, Germany

Professional Experience

7/2014-6/2017: Resident, Yale-New Haven Hospital, New Haven, CT
7/2017-6/2018: Chief Resident, Yale-New Haven Hospital, New Haven, CT
7/2018-6/2020: Fellow, Memorial Sloan Kettering Cancer Center, New York, NY

Other Experience and Professional Memberships

Member American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH)

Main Scientific Publications

Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel MA, Cai SF, Miles LA, Bowman RL, Geyer MB, Dunbar A, Epstein-Peterson ZD, McGovern E, Schulman J, Glass JL, Taylor J, Viny AD, Stein EM, Getta B, Arcila ME, Gao Q, Barker J, Shaffer BC, Papadopoulos EB, Gyurkocza B, Perales MA, Abdel-Wahab O, Levine RL, Giralt SA, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman MS, Roshal M, Goldberg AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. *Am J Hematol.* 2023 Jan;98(1):79-89. PMID: 36251406, <https://doi.org/10.1002/ajh.26757>

Shimony S, Rozental A, Bewersdorf JP, Goldberg AD, Stein EM, Grimshaw AA, Stone RM, DeAngelo DJ, Wolach O, **Stahl M**. Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis. *Haematologica.* 2022 Dec 1;107(12):2955-2960. PMID: 36453519, PMCID: PMC9713559, <https://doi.org/10.3324/haematol.2022.281453>

Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, **Stahl M**. Venetoclax-based salvage therapy in patients with



relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leuk Lymphoma. 2022 Oct 26;1-9. PMID: 36287540, <https://doi.org/10.1080/10428194.2022.2136952>

Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, **Stahl M***. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022 Aug 29;122:106942. PMID: 36108424, [https://doi.org/S0145-2126\(22\)00168-0](https://doi.org/S0145-2126(22)00168-0)

Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boulwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Adv. 2022 Oct 19. PMID: 36260702, <https://doi.org/bloodadvances.2022008747>

Stahl M*, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021 Mar 9;5(5):1552-1564. PMID: 33687434, PMCID: PMC7948282, <https://doi.org/10.1182/bloodadvances.2020003734>

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 Jul 24;2(14):1765-1772. PMID: 30037803, PMCID: PMC6058241, <https://doi.org/10.1182/bloodadvances.2018019414>

Zeidan AM, Platzbecker U, Bewersdorf JP, **Stahl M**, Adès L, Borate U, Bowen DT, Buckstein RJ, Brunner AM, Carraway HE, Daver NG, Díez-Campelo M, de Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. Blood. 2023 Feb 1. PMID: 36724453, <https://doi.org/blood.2022018604>
